SG11201603063WA - Compounds for use in prevention and treatment of neurodegenerative diseases and pain - Google Patents
Compounds for use in prevention and treatment of neurodegenerative diseases and painInfo
- Publication number
- SG11201603063WA SG11201603063WA SG11201603063WA SG11201603063WA SG11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA
- Authority
- SG
- Singapore
- Prior art keywords
- pain
- prevention
- compounds
- treatment
- neurodegenerative diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361894699P | 2013-10-23 | 2013-10-23 | |
PCT/US2014/061734 WO2015061426A1 (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201603063WA true SG11201603063WA (en) | 2016-05-30 |
Family
ID=52993493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603063WA SG11201603063WA (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Country Status (14)
Country | Link |
---|---|
US (1) | US10301348B2 (en) |
EP (1) | EP3060566B1 (en) |
JP (1) | JP6534997B2 (en) |
KR (1) | KR102313314B1 (en) |
CN (1) | CN106414456B (en) |
AU (1) | AU2014340114B2 (en) |
BR (1) | BR112016008901B1 (en) |
CA (1) | CA2927699C (en) |
IL (1) | IL245103B (en) |
MX (1) | MX367707B (en) |
RU (1) | RU2695358C2 (en) |
SG (1) | SG11201603063WA (en) |
WO (1) | WO2015061426A1 (en) |
ZA (1) | ZA201603118B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107614686A (en) | 2015-05-29 | 2018-01-19 | 小利兰·斯坦福大学托管委员会 | Nucleoside reagents for reducing deleterious activity of genes containing extended nucleotide repeats |
WO2018140734A1 (en) | 2017-01-27 | 2018-08-02 | Academia Sinica | Compound with analgesic effect for use in prevention and treatment of pain |
WO2023154804A2 (en) * | 2022-02-10 | 2023-08-17 | Academica Sinica | Method of treating spinal cord injury and composition for use therein |
TW202416962A (en) * | 2022-07-07 | 2024-05-01 | 中央研究院 | Method of treating schizophrenia and composition for use therein |
TW202435868A (en) * | 2022-12-29 | 2024-09-16 | 中央研究院 | Method of treating sleep disruptions and composition for use therein |
WO2024196760A1 (en) * | 2023-03-17 | 2024-09-26 | Academia Sinica | Method of treating tuberous sclerosis complex or epilepsy and composition for use therein |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8274187A (en) * | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Heteroaromatic derivatives of adenosine |
US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
EP0550631B1 (en) * | 1990-09-25 | 1997-01-02 | Rhone-Poulenc Rorer International (Holdings) Inc. | Compounds having antihypertensive and anti-ischemic properties |
US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
UY27939A1 (en) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | COMPOUNDS |
KR101830623B1 (en) * | 2009-11-13 | 2018-02-21 | 아카데미아 시니카 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Disease |
CN102812033B (en) * | 2009-12-10 | 2015-11-25 | 中国医学科学院药物研究所 | N6-substituted adenosines derivative and N6-substituted adenines derivative and uses thereof |
JP6208693B2 (en) * | 2012-02-09 | 2017-10-04 | ブランドバンプス,エルエルシー | Decorated detectable warning panel with improved grip |
WO2013120078A1 (en) * | 2012-02-11 | 2013-08-15 | Academia Sinica | Methods and compositions for treating pain |
-
2014
- 2014-10-22 JP JP2016525563A patent/JP6534997B2/en active Active
- 2014-10-22 CA CA2927699A patent/CA2927699C/en active Active
- 2014-10-22 AU AU2014340114A patent/AU2014340114B2/en active Active
- 2014-10-22 EP EP14855465.2A patent/EP3060566B1/en active Active
- 2014-10-22 US US15/031,711 patent/US10301348B2/en active Active
- 2014-10-22 CN CN201480058727.3A patent/CN106414456B/en active Active
- 2014-10-22 MX MX2016005174A patent/MX367707B/en active IP Right Grant
- 2014-10-22 KR KR1020167013624A patent/KR102313314B1/en active Active
- 2014-10-22 BR BR112016008901-4A patent/BR112016008901B1/en active IP Right Grant
- 2014-10-22 WO PCT/US2014/061734 patent/WO2015061426A1/en active Application Filing
- 2014-10-22 SG SG11201603063WA patent/SG11201603063WA/en unknown
- 2014-10-22 RU RU2016118282A patent/RU2695358C2/en active
-
2016
- 2016-04-13 IL IL245103A patent/IL245103B/en active IP Right Grant
- 2016-05-10 ZA ZA2016/03118A patent/ZA201603118B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2014340114B2 (en) | 2018-10-18 |
MX367707B (en) | 2019-09-03 |
KR20160086852A (en) | 2016-07-20 |
CA2927699C (en) | 2022-07-05 |
RU2695358C2 (en) | 2019-07-23 |
JP2016535019A (en) | 2016-11-10 |
MX2016005174A (en) | 2016-08-11 |
IL245103A0 (en) | 2016-06-30 |
NZ719740A (en) | 2021-02-26 |
CN106414456A (en) | 2017-02-15 |
IL245103B (en) | 2019-02-28 |
CN106414456B (en) | 2018-12-14 |
EP3060566B1 (en) | 2018-09-05 |
EP3060566A4 (en) | 2017-06-14 |
BR112016008901B1 (en) | 2022-08-23 |
ZA201603118B (en) | 2019-04-24 |
WO2015061426A1 (en) | 2015-04-30 |
US20160264613A1 (en) | 2016-09-15 |
CA2927699A1 (en) | 2015-04-30 |
KR102313314B1 (en) | 2021-10-19 |
BR112016008901A2 (en) | 2020-05-12 |
RU2016118282A3 (en) | 2018-06-18 |
RU2016118282A (en) | 2017-11-28 |
JP6534997B2 (en) | 2019-06-26 |
US10301348B2 (en) | 2019-05-28 |
EP3060566A1 (en) | 2016-08-31 |
AU2014340114A1 (en) | 2016-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1222530A1 (en) | Microclosures and related methods for skin treatment | |
IL239368A0 (en) | Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases | |
PL3031826T3 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
HK1221178A1 (en) | Cabozantinib dosage form and use in the treatment of cancer | |
EP2836270A4 (en) | Systems and methods related to the treatment of back pain | |
EP2943189A4 (en) | Methods and comp0stions for treatment of demyelinating diseases | |
ZA201603118B (en) | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | |
HK1220352A1 (en) | Il-33 and treatment of neurodegenerative diseases il-33 | |
GB201311361D0 (en) | Compounds and their therapeutic use | |
ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
SI3598971T1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
HK1222585A1 (en) | Dihydroetorphine for the provision of pain relief and anaesthesia | |
IL246036B (en) | Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain | |
ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
EP2964227A4 (en) | Treatment and prophylaxis of kidney diseases | |
EP2986294A4 (en) | Compounds for treatment of pain | |
GB201308736D0 (en) | Compounds and their therapeutic use | |
HK1218882A1 (en) | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases | |
ZA201506396B (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
IL259383A (en) | Compound for use in the prevention and treatment of neurodegenerative diseases | |
EP2986295A4 (en) | Compounds for treatment of pain | |
HUP1300454A2 (en) | Pharmaceutical compositions for the treatment and prevention of tumorous diseases | |
GB201317373D0 (en) | Treatment and prevention of cancer | |
GB201309001D0 (en) | Methods for prevention and treatment of preeclampsia | |
GB201317804D0 (en) | Therapeutic compounds and their use |